DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Harrington KJ, Puzanov I, Hecht JR. et al.
Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
Expert Rev Anticancer Ther 2015;
15: 1389-1403
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.